Loading...
•
Dec 31, 2020
Inovio Q4 2020 Earnings Report
Inovio reported financial results and provided a business update.
Key Takeaways
Inovio reported Q4 2020 financial results, with a total revenue of $5.6 million and a net loss of $24.3 million, or $0.14 per share. The company highlighted progress in its HPV and oncology programs, including positive results from the REVEAL 1 Phase 3 clinical trial for VGX-3100 and advancements in its COVID-19 vaccine program.
VGX-3100 REVEAL 1 Phase 3 clinical trial met primary and secondary endpoints among all evaluable subjects.
Completed enrollment of 400 subjects in the Phase 2 segment of the INNOVATE Phase 2/3 clinical trial for INO-4800.
Addressed new COVID variants by evaluating their impact on the immune profile of INO-4800 and developing next-generation vaccine candidates.
Phase 1 clinical data from INO-4800 was published in The Lancet’s EClinicalMedicine.
Inovio
Inovio
Inovio Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
INOVIO is focused on advancing its DNA medicines platform across HPV-associated diseases, cancer, and infectious diseases. The company is committed to completing its Phase 2 segment in the second quarter and seeking to advance to the Phase 3 portion of the trial.
Positive Outlook
- VGX-3100 met primary and secondary endpoints in REVEAL 1 trial.
- INO-4800 Phase 1 data published in The Lancet’s EClinicalMedicine.
- INOVIO is developing next-generation, pan-COVID vaccine candidates.
- INOVIO received a $37.6 million grant from DARPA to develop anti-SARS-CoV-2-specific dMAbs®
- INOVIO is evaluating the impact of newly circulating strains of the SARS-CoV-2 virus on the immune profile of INO-4800
Challenges Ahead
- Uncertainties inherent in pre-clinical studies and clinical trials.
- Ability to secure sufficient manufacturing capacity.
- Availability of funding to support continuing research and studies.
- Potential availability of alternative therapies or treatments.
- Issues involving patents and product liability.